Asian Spectator

5 Ways Small Businesses Can Benefit from Utilizing Cryptocurrencies

Over the last couple of years, cryptocurrencies have become a very important part of the financial landscape. Still, the alternative nature of these types of financial assets still keeps most of the small businesses on the fence about the whole matter. How can these assets benefit your organiz...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Xinyi Glass Announces 2020 Interim Results

Business Remains Resilient Amid Challenging Market EnvironmentNet Profit at HK$1.38 BillionMaintains High Dividend Payout Ratio Interim Dividend at 17.0 HK Cents per SharePrepares for Industry Re...

Tile(TM) and Skullcandy Create Most Advanced True Wireless Fin...

SYDNEY, Aug. 4, 2020 /PRNewswire-AsiaNet/ -- -- Tile(TM) Makes Skullcandy Earbuds Findable Even When in Charging Case, Offers Support of Global Finding Network When Lost Tile ( https://c212...

GSB Gold Standard Corporation, Josip Heit and the Blockchain Technology



HAMBURG, GERMANY - NEWSAKTUELL - 3 Aug 2020 - The blockchain technology is one of the most discussed innovations of the digital transformation of economy and society, which is...

Shanghai Electric has been awarded EPC contract for 5th phase ...

SHANGHAI, Aug. 3, 2020 /PRNewswire-AsiaNet/ Shanghai Electric Group has been appointed by ACWA Power of Saudi Arabia, as the Engineering, Construction and Procurement (EPC) contractor, to de...

GranBio and NextChem sign partnership to develop cellulosic et...

SÃO PAULO and ROME, August 3, 2020 /PRNewswire-AsiaNet/ -- GranBio, a 100% Brazilian industrial biotechnology company, and NextChem, Maire Tecnimont's subsidiary for energy transition...

CIFF Guangzhou 2020 Successfully Concludes: Striving to Drive ...

GUANGZHOU, China, Aug. 3, 2020/PRNewswire-AsiaNet/-- CIFF Guangzhou 2021 scheduled between March 18-21 and March 28-31, 2021.The 45th CIFF Guangzhou 2020 successfully concluded on July 30. T...

Huawei Announces Global Rollout of New Device Gaming Hub - HUA...

BEIJING, Aug. 3, 2020 /PRNewswire-AsiaNet/ -- Huawei today announced the rollout of its official game service and distribution platform HUAWEI GameCenter in 33 countries and regions worldwid...

Changsha: the Development of Emerging Industry Chain Stimulate...

CHANGSHA, China, Aug. 3, 2020 /Xinhua-AsiaNet/-- Changsha, the capital city of Hunan province in central China, is now enjoying a recovery of economic and social vitality in the post-epidemi...

Magazine

Australian startup CareApp receives funding injection to expand app

Australian based startup CareApp has recently raised over $500,000 in funding including $250,000 provided by the South Australian State Government to rapidly expand and scale up their smartphone...

Shaparency launches to enable businesses to go fully digital

New venture developed for post-Covid-19 corporate landscape London-based start-up Shaparency, which has been established in response to the business conditions resulting from Covid-19, announces ...

Specops Significant Cyber Attacks

The prevalence and severity of cyber attacks are increasing at an alarming rate every year. So much so, that statistics from Cybersecurity Ventures estimate that cybercrime will cost the global ...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion

office@NewsCompany.net